SELS DE CARBOXAMIDE D'AMINOIMIDAZOLE UTILES DANS LA PREVENTION ET LE TRAITEMENT DES MALADIES DU FOIE

SALTS OF AMINOIMIDAZOLE CARBOXAMIDE USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASES

Abrégé français

L'invention concerne des compositions et des techniques, permettant de prévenir et de traiter une lésion tissulaire provoquée par l'alcool, par des médicaments thérapeutiquement utiles, ainsi que par des toxines industrielles, alimentaires et environnementales, à l'aide d'une quantité efficace de sels de carboxamide d'aminoimidazole.

Abrégé anglais

Compositions and methods are described for the prevention and treatment of
tissue damage caused by alcohol, therapeutically
helpful drugs as well as industrial, dietary and environmental toxins, using
an effective amount of salts of aminoimidazole
carboxamide.

Revendications

We claim:

1. A use of 5-aminoimidazole-4-carboxamide orotate for the manufacture of a
medicament for inhibiting tissue damage caused by methotrexate.

2. A use of 5-aminoimidazole-4-carboxamide orotate for the manufacture of a
medicament for inhibiting liver damage caused by methotrexate.

3. The use of 5-aminoimidazole-4-carboxamide orotate for the manufacture of a
medicament for inhibiting tissue damage caused by methotrexate, according to
claim 1, further comprising an antioxidant selected from the group consisting
of
N-acetylcysteine, vitamin E, vitamin A and its derivatives, vitamin C,
glutathione,
cysteine, methionine and 2 mercaptoethanol.

4. The use of 5-aminoimidazole-4-carboxamide orotate for the manufacture of a
medicament for inhibiting liver damage caused by methotrexate, according to
claim 2, further comprising an antioxidant selected from the group consisting
of
N-acetylcysteine, vitamin E, vitamin A and its derivatives, vitamin C,
glutathione,
cysteine, methionine and 2 mercaptoethanol.

5. The use of 5-aminoimidazole-4-carboxamide orotate according to any one of
claims 1 to 4, wherein the medicament is for oral, intravenous, transcutaneous
or
transdermal aministration.

29


6. A use of 5-aminoimidazole-4-carboxamide orotate for inhibiting tissue
damage
caused by methotrexate.

7. A use of 5-aminoimidazole-4-carboxamide orotate for inhibiting liver damage
caused by methotrexate.

8. The use of 5-aminoimidazole-4-carboxamide orotate for inhibiting tissue
damage
caused by methotrexate, according to claim 1, further comprising an
antioxidant
selected from the group consisting of N-acetylcysteine, vitamin E, vitamin A
and
its derivatives, vitamin C, glutathione, cysteine, methionine and 2
mercaptoethanol.
9. The use of 5-aminoimidazole-4-carboxamide orotate for inhibiting liver
damage
caused by methotrexate, according to claim 2, further comprising an
antioxidant
selected from the group consisting of N-acetylcysteine, vitamin E, vitamin A
and
its derivatives, vitamin C, glutathione, cysteine, methionine and 2
mercaptoethanol.

-30-

Description

CA 02368165 2007-07-27

SALTS OF AMINOIMIDAZOLE CARBOXAMIDE
USEFUL IN THE PREVENTION AND
TREATMENT OF LIVER DISEASES

1. INTRODUCTION

The present invention is directed to methods and compositions for the
prevention
and/or inhibition of tissue injury caused by alcohol, therapeutically useful
drugs as well as by
industrial, dietary and environmental toxins, by administration of salts of
aminoimidazole
carboxamide (AICA). Use of the entire group of organic acid salts and
inorganic acid salts of 5-
aminoimidazole carboxamide rather than only those obtained from orotic acid
are encompassed
by the methods of the invention. For example, AICA may also be reacted with
aliphatic acids
including, but not limited to, lactic, succinic, maleic, citric, and tartaric
or with sugar acids such
as gluconic, galactonic, etc., particularly penta and poly hydroxycarboxylic
acids to form organic
acid salts, or AICA may be reacted with inorganic acids including, but not
limited to, hydrohloric
and phosphoric acids, to form inorganic salts suitable for use according to
the methods of the
present invention.

The methods involve administering to an individual consuming alcohol,
therapeutic drugs and/or exposed to xenobiotic agents, an effective dose of a
salt of


CA 02368165 2001-10-18
WO 00/78311 PCTIUSOO/10690
aminoimidazole carboxamide with or without antioxidants, including, but not
limited to

vitamin E, vitamin C, vitamin A and its derivatives, glutathione, N-
acetylcysteine or magnesium
gluconate. In the practice of the invention, compositions containing salts of
AICA are used to
detoxify harmful and noxious agents or toxins, to inhibit bioactivation of
agents to harmful
electrophiles or free radicals, to inhibit suppression of cell-mediated or
humoral immune
mechanisms, to stimulate the regeneration of target cells of the damaged issue
and to inhibit the
failure of energy supply. Preferred compositions of the invention are those
which specifically or
preferentially inhibit tissue injury involving , but not limited to,
hepatocytes, nonparenclymal
cells, endothelial cells, pit cells and other cells lining the hepatic
sinusoids and bile duets.

2. BACKGROUND OF THE INVENTION
2.1 SALTS OF AMINOIMIDAZOLE CARBOXAMIDE

AICA orotate, also referred to as "Orazamide Orotate" is incorporated into
animal
nucleic acids and possesses the ability to prevent necrosis of liver induced
by acute and chronic
hepatic damage in animals. Miller, C.S. et al., 1950, Science 112: 654.

2.1.1 CHEMICAL NATURE AND PROPERTIES OF SALTS OF
AMINOIMIDAZOLE CARBOXAMIDE

Orazamide is available in different forms as: 5-aminoimidazole-4-carboxamide
orotate, 4-amino-5-imidazole carboxamide orotate or a combination of 1,2,3,6-
tetrahydro-2,6-
dioxo-4-pyrimidine carboxylic acid with 5-amino-1 H-imidazole-4-carboxamide
(1:1) or a
combination of orotic acid with 5(or 4)-aminoimidazole-4(or 5)-carboxamide
(1:1). The C5
amine group on the imidazole ring can be attached to the C4 carboxyl group of
orotic acid or any
other organic acid which is chemically compatible to the body:


CA 02368165 2001-10-18
WO 00/78311 PCT/US00/10690
W2. 0
CONH2 N
6
4
NH '=HOOC NH
3N\ 2
3

+ a+ooc aad acbaaramide ocntua
2.1.2 METABOLIC EFFECT OF OROTIC ACID

Any kind of organic or inorganic acid which is clinically compatible with the
body
may be selected to be reacted with AICA, an intermediate in the purine
pathway. Especially
desirable are orotic, lactic, succinic, maleic, citric, tartaric, gluconic,
galactonic, hydrochloric,
phosphoric and penta or poly hydroxycarboxylic acids.

Orotic acid is an intermediate in the pyrimidine pathway and its main source
in
human and animal diet is bovine milk and its products.

2.2 ALCOHOL AND LIVER DISEASE

An association of alcohol with damage to the liver rests primarily on the
clinical
observation that cirrhosis occurs in-patients consuming large amounts of
ethanol. Ethanol has

.3


CA 02368165 2001-10-18
WO 00/78311 PCT/US00/10690
been shown to have a variety of toxic effects on livers in otherwise normal
animals, including
normal men and women.

Alcohol abuse costs the U.S. more than one hundred and sixteen billion dollars
per year, of which about twelve percent is for direct costs of medical care.
Advertising, counter
advertising and depiction in the public media, 1986, JAMA 256 : 1485. The
basic reason for the
large epidemic of alcohol-related disease is that ethanol is an effective drug
in relieving anxiety,
depression and the pressures of modem society. The easy availability of
ethanol and the social
acceptability of ethanol consumption are advertised widely and aggressively.
The public seems
unaware that chronic use of ethanol in the absence of addiction can lead to
serious medical
illness and/or the development of social consequences. About three quarters of
the population of
the United States uses ethanol. The incidence of alcoholism in the United
States is
approximately seven percent, being higher for men (11 percent) than for women
(4.08 percent).
Alcohol Health and Research World, 1995, 18 : 243-8.

Prevention and/or treatment of alcoholism is a problem for which there are no
certain answers. Therefore, an understanding of the biochemical basis for the
hepatotoxicity of
ethanol and its eventual control may provide an effective means to reduce and
manage alcohol
related liver diseases and medical complications.